FDA approves autoinjector option for upcoming adalimumab biosimilar

The FDA has given the green light to a new autoinjector option for the interchangeable adalimumab biosimilar Cyltezo, just weeks ahead of its scheduled debut in the United States, according to a press release from the manufacturer.“The FDA approval of the Cyltezo pen is great news for patients living with chronic inflammatory diseases who may prefer administering the medication needed to manage their conditions via an autoinjector,” Stephen Pagnotta, executive director and biosimilar commercial lead at Boehringer Ingelheim, said in the release. “We’re excited to beRead More